A

nd so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you know, our treasured signal to daydream about weekend plans. Our agenda, for the moment, is rather modest. We hope to catch up on some sundry chores, spend time with our short person, and possibly visit the Pharmalot ancestors. And what about you? This may be a good time to take in a moving picture. For those with a keen sense of discipline, you can self-flagellate by readying your taxes. Or you could catch up on the steady stream of presidential tweets, such as they are. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

A focus on fewer diseases, along with cuts in labs and staff, has yielded a more than fourfold increase in research productivity at AstraZeneca (AZN)Reuters writes. Why? There was a marked drop in the number of projects started at the discovery stage, with the total falling to just 76 in 2012 to 2016 from 287 in 2005 to 2010. “We’re working on far fewer programs and the probability of success on those programs is going up,” says one AstraZeneca exec.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • When you lose $7 billion in sales off your blockbuster drug Crestor, with nothing in the pipeline to compensate, it does tend to put a crimp in your R&D budget.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.